p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses.

The mitogen-activated protein (MAP) kinase protein family has a critical role in cellular signaling events, with MAP kinase p38alpha acting in inflammatory processes and being an important drug discovery target. MAP kinase drug design efforts have focused on small-molecule inhibitors of the ATP catalytic site, which exhibit dose-limiting adverse effects. Therefore, characterizing other potential sites that bind substrates, inhibitors, or allosteric effectors is of great interest. Here, we present the crystal structure of human p38alpha MAP kinase, which has a lead compound bound both in the active site and in the lipid-binding site of the C-terminal cap. This C-terminal cap is formed from an extension to the kinase fold, unique to the MAP kinase and cyclin-dependent kinase families and glycogen synthase kinase 3. Binding of this lead, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine, to wild-type p38alpha induces movement of the C-terminal cap region, creating a hydrophobic pocket centered around residue Trp197. Computational analysis of this C-terminal domain pocket indicates notable flexibility for potentially binding different-shaped compounds, including lipids, oxidized arachidonic acid species such as leukotrienes, and small-molecule effectors. Furthermore, our structural results defining the open p38alpha C-lobe pocket provide a detailed framework for the design of novel small molecules with affinities comparable to active-site binders: to bind and potentially modulate the shape and activity of p38alpha in predetermined ways. Moreover, these results and analyses of p38alpha suggest strategies for designing specific binding compounds applicable to other MAP kinases, as well as the cyclin-dependent kinase family and glycogen synthase kinase 3beta that also utilize the C-terminal insert in their interactions.

[1]  Radha Akella,et al.  Substrate and docking interactions in serine/threonine protein kinases. , 2007, Chemical reviews.

[2]  Stefano Trapani,et al.  AMoRe: classical and modern , 2007, Acta crystallographica. Section D, Biological crystallography.

[3]  Radha Akella,et al.  Unique MAP Kinase binding sites. , 2008, Biochimica et biophysica acta.

[4]  Jui‐I Chao,et al.  Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. , 2008, Toxicology letters.

[5]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[6]  J. Tainer,et al.  A mutation in the human cyclin-dependent kinase interacting protein, CksHs2, interferes with cyclin-dependent kinase binding and biological function, but preserves protein structure and assembly. , 1996, Journal of molecular biology.

[7]  L. Tong,et al.  Crystallization and preliminary crystallographic analysis of recombinant human p38 MAP kinase , 1997, Protein science : a publication of the Protein Society.

[8]  D. Kipling,et al.  Werner Syndrome as an example of inflamm-aging: possible therapeutic opportunities for a progeroid syndrome? , 2006, Rejuvenation research.

[9]  J. Tainer,et al.  Biogenesis of chemotactic molecules by the arachidonate lipoxygenase system of platelets , 1975, Nature.

[10]  John A. Tainer,et al.  X-ray solution scattering (SAXS) combined with crystallography and computation: defining accurate macromolecular structures, conformations and assemblies in solution , 2007, Quarterly Reviews of Biophysics.

[11]  Y. Lee,et al.  Corrigendum to “Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells” [Toxicol. Lett. 179 (June(2)) (2008) 63–70] , 2008 .

[12]  Gabriella De Vita,et al.  p38α MAP Kinase as a Sensor of Reactive Oxygen Species in Tumorigenesis , 2007 .

[13]  J. Madwed,et al.  Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). , 2003, Journal of medicinal chemistry.

[14]  L. Bardwell,et al.  Mechanisms of MAPK signalling specificity. , 2006, Biochemical Society transactions.

[15]  David S. Goodsell,et al.  Automated docking of ligands to an artificial active site: augmenting crystallographic analysis with computer modeling , 2003, J. Comput. Aided Mol. Des..

[16]  L. Tong,et al.  A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.

[17]  S. Reed,et al.  A kinase-independent function of Cks1 and Cdk1 in regulation of transcription. , 2005, Molecular cell.

[18]  Andrew D Sharrocks,et al.  ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif. , 2004, The Biochemical journal.

[19]  F. Wyllie,et al.  The Role of Cellular Senescence in Werner Syndrome , 2007, Annals of the New York Academy of Sciences.

[20]  Jiahuai Han,et al.  Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38α, through MKK3/6-independent and -dependent Mechanisms* , 2007, Journal of Biological Chemistry.

[21]  A. Cuadrado,et al.  p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. , 2007, Cancer cell.

[22]  J. Tainer,et al.  Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase , 2008, Nature chemical biology.

[23]  J. Shelhamer,et al.  Leukotriene D(4) induces gene expression in human monocytes through cysteinyl leukotriene type I receptor. , 2008, The Journal of allergy and clinical immunology.

[24]  A. Doweyko,et al.  Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions. , 2005, Current topics in medicinal chemistry.

[25]  Ron Diskin,et al.  A novel lipid binding site formed by the MAP kinase insert in p38 alpha. , 2008, Journal of molecular biology.

[26]  S. Klassen,et al.  Ceramide activates a mitochondrial p38 mitogen-activated protein kinase: A potential mechanism for loss of mitochondrial transmembrane potential and apoptosis , 2005, Molecular and Cellular Biochemistry.

[27]  S. Colowick,et al.  Methods in Enzymology , Vol , 1966 .

[28]  SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS , 1998 .

[29]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[30]  John C. Lee,et al.  p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. , 2001, Progress in medicinal chemistry.

[31]  Jui‐I Chao,et al.  Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. , 2007, Toxicology and applied pharmacology.

[32]  B. Kamińska MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. , 2005, Biochimica et biophysica acta.

[33]  John A Tainer,et al.  Crystal Structure and Mutational Analysis of the Human CDK2 Kinase Complex with Cell Cycle–Regulatory Protein CksHs1 , 1996, Cell.

[34]  D. Lawrence,et al.  Multiple Regions of MAP Kinase Phosphatase 3 Are Involved in Its Recognition and Activation by ERK2* , 2001, The Journal of Biological Chemistry.

[35]  E. Goldsmith,et al.  Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[36]  L. Pearl,et al.  Structural basis for recruitment of glycogen synthase kinase 3β to the axin—APC scaffold complex , 2003, The EMBO journal.

[37]  Discovering new MAP kinase inhibitors. , 2006, Chemistry & biology.

[38]  P. Dennis,et al.  Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. , 2003, Journal of the American Chemical Society.

[39]  M. Miloso,et al.  Neurotoxicity of Platinum Compounds: Comparison of the Effects of Cisplatin and Oxaliplatin on the Human Neuroblastoma Cell Line SH-SY5Y , 2004, Journal of Neuro-Oncology.

[40]  D. Goodsell,et al.  Automated prediction of ligand‐binding sites in proteins , 2007, Proteins.

[41]  A. Cuenda,et al.  p38 MAP-kinases pathway regulation, function and role in human diseases. , 2007, Biochimica et biophysica acta.

[42]  J. Blank,et al.  p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. , 2003, Molecular biology of the cell.

[43]  Ricardo M Biondi,et al.  Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. , 2003, The Biochemical journal.

[44]  Lifeng Geng,et al.  Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase. , 2007, Journal of medicinal chemistry.

[45]  J. Tainer,et al.  Screening a peptidyl database for potential ligands to proteins with side‐chain flexibility , 1998, Proteins.

[46]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[47]  Hui-yu Liu,et al.  p38 Mitogen-activated Protein Kinase Mediates Free Fatty Acid-induced Gluconeogenesis in Hepatocytes* , 2006, Journal of Biological Chemistry.

[48]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[49]  E. Nishida,et al.  A conserved docking motif in MAP kinases common to substrates, activators and regulators , 2000, Nature Cell Biology.

[50]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[51]  L. Johnson,et al.  Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. , 2001, Molecular cell.

[52]  Jiahuai Han,et al.  Mitogen‐activated protein kinase p38 defines the common senescence‐signalling pathway , 2003, Genes to cells : devoted to molecular & cellular mechanisms.

[53]  E. Goldsmith,et al.  The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Tainer,et al.  Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel. , 1995, Journal of molecular biology.

[55]  Masahiko Hibi,et al.  c-Jun Can Recruit JNK to Phosphorylate Dimerization Partners via Specific Docking Interactions , 1996, Cell.

[56]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[57]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[58]  Michel F. Sanner,et al.  Hierarchical and multi-resolution representation of protein flexibility , 2006, Bioinform..

[59]  John A Tainer,et al.  Full‐length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2 , 2003, The EMBO journal.

[60]  H. Saito,et al.  Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. , 2005, Molecular cell.

[61]  L. Mahadevan,et al.  Anisomycin Selectively Desensitizes Signalling Components Involved in Stress Kinase Activation and fos andjun Induction , 1998, Molecular and Cellular Biology.

[62]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[63]  C. Murga,et al.  Interfering with MAP Kinase Docking Interactions: Implications and Perspectives for the p38 Route , 2007, Cell cycle.

[64]  Y-T Chen,et al.  Areca nut extracts-activated secretion of leukotriene B4, and phosphorylation of p38 mitogen-activated protein kinase and elevated intracellular calcium concentrations in human polymorphonuclear leukocytes. , 2007, Journal of periodontal research.

[65]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[66]  J. Tainer,et al.  Structural Basis for FEN-1 Substrate Specificity and PCNA-Mediated Activation in DNA Replication and Repair , 2004, Cell.

[67]  A. Sharrocks,et al.  Docking domains and substrate-specificity determination for MAP kinases. , 2000, Trends in biochemical sciences.

[68]  M. Karin,et al.  Mammalian MAP kinase signalling cascades , 2001, Nature.

[69]  A. Sharrocks,et al.  Selective Targeting of MAPKs to the ETS Domain Transcription Factor SAP-1* , 2001, The Journal of Biological Chemistry.

[70]  John A Tainer,et al.  DNA double-strand break repair from head to tail. , 2002, Current opinion in structural biology.

[71]  O. Werz,et al.  p38 MAP kinase mediates stress‐induced leukotriene synthesis in a human B‐lymphocyte cell line , 2001, Journal of leukocyte biology.